Literature DB >> 3079600

Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary level.

F F Casanueva, L Villanueva, C Dieguez, J A Cabranes, Y Diaz, B Szoke, M F Scanlon, A V Schally, A Fernandez-Cruz.   

Abstract

The role of acetylcholine (Ach) in the regulation of human GH secretion was assessed using atropine, which selectively blocks cholinergic muscarinic receptors. Paired tests were performed in seven normal subjects using GH-releasing hormone (GHRH) 1-44 (1 microgram/kg iv), with and without atropine pretreatment (1 mg im). The GHRH 1-44-induced GH secretory peak [20.7 +/- 4.5 (SEM) ng/ml] was completely blocked by atropine administration (2.3 +/- 0.6 ng/ml) (P less than 0.01). To determine whether this atropine blockade was at the pituitary level, a series of in vitro studies were conducted using monolayer cultures of cells from bovine anterior pituitary glands. GHRH 1-44 (10(-8) M) stimulated bovine GH release (11.1 +/- 1.5 micrograms/ml) as compared to control values (5.1 +/- 0.4 microgram/ml) (P less than 0.01). This response was not altered by 10(-6) M atropine (14.9 +/- 0.9 microgram/ml). Similar results were obtained with GHRH, 10(-9) M, with or without atropine, 10(-7) M. Addition of 10(-6) M Ach to the incubation medium significantly increased bovine GH release (12.7 +/- 1.2 microgram/ml) and the effect of 10(-6) M Ach and 10(-8) M GHRH was additive (20.9 +/- 2.1 micrograms/ml) (P less than 0.01). Similar results were obtained with Ach, 10(-5) M, and GHRH, 10(-9) M. Atropine or eserine alone did not alter basal GH secretion, and atropine blocked Ach-stimulating activity. In conclusion, atropine blockade of GHRH-induced GH secretion appears to be exerted at a site other than pituitary.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3079600     DOI: 10.1210/jcem-62-1-186

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Cadmium effects on dopamine turnover and plasma levels of prolactin, GH and ACTH.

Authors:  A Lafuente; N Márquez; D Pazo; A I Esquifino
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

Review 2.  Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; V Locatelli; E Ghigo; S G Cella; S Loche; C Pintor; F Camanni
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

3.  A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.

Authors:  E Ghigo; S Goffi; E Arvat; E Imperiale; G M Boffano; M R Valetto; E Mazza; I Santi; A Magliona; M F Boghen
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

4.  Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa.

Authors:  S Fassino; F Lanfranco; G Abbate Daga; V Mondelli; S Destefanis; G G Rovera; F Camanni; E Ghigo; E Arvat; L Gianotti
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.